10x Genomics, Inc.
TXG- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001770787
In the last 90 days, 10x Genomics, Inc. insiders filed 0 open-market purchases and 10 sales; 396 institutions reported holding it in 13F filings for Q2 2026, worth $4.92B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $11.1M in total
- 10
- 13F holdersQ2 2026, +68 vs. previous quarter
- 396
- 13F valueReported value at the end of Q2 2026
- $4.92B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $642.8M
- +5.2% year over year
- Net income, FY2025
- -$43.5M
- No comparable prior period
- Free cash flow, FY2025
- $130.1M
- No comparable prior period
- Revenue, Q3 FY2026
- $150.7M
- +1.1% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 12.5M
- Shares sold short
- Change
- −259.1K
- −2.0% vs. previous
- Days to cover
- 4.13
- At average daily volume
Superinvestors holding TXG, Q2 2026
Go to the superinvestors tab2 superinvestors report holding 10x Genomics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.4%
10x Genomics, Inc.'s share of the portfolio
- Shares
- 403,100
- Value
- $15.5M
Latest insider trades
See all insider tradesOpen-market purchases and sales by 10x Genomics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:30 PM ET | Sep 22 | 2 days | Suliman ShehnaazDirector | SSaleClass A Common Stock | −5.72K | $81.19 | −$464.7K | −19.4%23.8K after | 5 lots10b5-1 |
| Sep 24, 2026 (view filing)4:29 PM ET | Sep 22 | 2 days | Saxonov SergeChief Executive Officer | SSaleClass A Common Stock | −25.0K | $81.22 | −$2.03M | −2.3%1.05M after | 5 lots10b5-1 |
| Sep 11, 2026 (view filing)4:47 PM ET | Sep 9 | 2 days | Taich AdamChief Financial Officer | SSaleClass A Common Stock | −46.4K | $64.57 | −$3.00M | −12.8%316.3K after | 3 lots10b5-1 |
| Sep 8, 2026 (view filing)7:00 PM ET | Sep 3 | 5 days | Stuelpnagel John RDirector | SSaleClass A Common Stock | −20.0K | $61.75 | −$1.24M | −5.7%328.4K after | 3 lots |
| Aug 28, 2026 (view filing)7:22 PM ET | Aug 26 | 2 days | Saxonov SergeChief Executive Officer | SSaleClass A Common Stock | −10.5K | $63.69 | −$667.9K | −1.0%1.08M after | 3 lots10b5-1 |
| Aug 26, 2026 (view filing)4:46 PM ET | Aug 24 | 2 days | Saxonov SergeChief Executive Officer | SSaleClass A Common Stock | −18.5K | $63.02 | −$1.17M | −1.7%1.09M after | |
| Aug 26, 2026 (view filing)4:44 PM ET | Aug 24 | 2 days | Taich AdamChief Financial Officer | SSaleClass A Common Stock | −17.2K | $63.02 | −$1.08M | −4.5%362.7K after | |
| Aug 26, 2026 (view filing)4:43 PM ET | Aug 24 | 2 days | Hindson Benjamin J.See Remarks | SSaleClass A Common Stock | −13.8K | $63.02 | −$870.9K | −2.8%488.2K after | |
| Aug 26, 2026 (view filing)4:42 PM ET | Aug 24 | 2 days | Suliman ShehnaazDirector | SSaleClass A Common Stock | −2.21K | $63.65 | −$140.5K | −7.0%29.5K after | 2 lots10b5-1 |
| Aug 17, 2026 (view filing)4:08 PM ET | Aug 13-14 | 4 days | Teichmann Sarah A.Director | SSaleClass A Common Stock | −7.55K | $57.25 | −$432.3K | −21.2%28.1K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 396 holdersThe largest institutional positions in 10x Genomics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 17,629,266 | $675.9M | 0.03% | −111,706−0.6% | Reduced |
| BlackRock, Inc. | 10,804,070 | $414.2M | 0.01% | +724,157+7.2% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 10,003,057 | $383.5M | 2.49% | −1,714,260−14.6% | Reduced |
| Vanguard Portfolio Management LLC | 6,982,492 | $267.7M | 0.01% | +69,556+1.0% | Added |
| Quantinno Capital Management LP | 5,469,698 | $209.7M | 0.25% | +57,937+1.1% | Added |
| Vanguard Capital Management LLC | 5,082,594 | $194.9M | 0.00% | −186,992−3.5% | Reduced |
| Price T Rowe Associates Inc | 4,539,007 | $174.0M | 0.02% | +4,375,792+2,681.0% | Added |
| Sumitomo Mitsui Trust Holdings, Inc. | 4,194,627 | $160.8M | 0.09% | −915,587−17.9% | Reduced |
| Nikko Asset Management Americas, Inc. | 4,192,517 | $160.7M | 2.07% | −911,661−17.9% | Reduced |
| Morgan Stanley | 3,351,911 | $128.5M | 0.01% | +695,558+26.2% | Added |
Holders of 5% or more of TXG
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of 10x Genomics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.60%18.5M shares | +4.80 ppfrom 10.80% | Feb 8, 202113 filings | Mar 6, 2026 | SEC |
| Price T Rowe Associates Inc | 13G | 11.70%14.0M shares | New | Sep 8, 20261 filing | Sep 8, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.60%8.50M shares | – | Jul 16, 20251 filing | Jul 16, 2025 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.93%6.98M shares | New | Apr 28, 20261 filing | Apr 28, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.24%6.17M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |